IDEAS home Printed from https://ideas.repec.org/a/spr/patien/v2y2009i2p105-112.html
   My bibliography  Save this article

Impact of Natalizumab on Patient-Reported Outcomes in a Clinical Practice Setting

Author

Listed:
  • Siddhesh Kamat
  • Krithika Rajagopalan
  • Judith Stephenson
  • Sonalee Agarwal

Abstract

Objective: To assess multiple sclerosis (MS) patients’ experience with natalizumab (TYSABRI®, Biogen Idec, Inc. and Elan Pharmaceuticals, Inc.) in a clinical practice setting. Methods: MS patients who were enrolled in the TOUCH (TYSABRI® Outreach Unified Commitment to Health) prescribing program and who had received their third natalizumab infusion participated in this study. Patient-reported measures included an overall quality-of-life (QOL) assessment, an adapted version of the Multiple Sclerosis Impact Scale-29 (MSIS-29), and pre-/post-disease level and functional status scores. MSIS-29 responses were modified to measure patient-perceived change since initiating natalizumab. Paired t-tests assessed pre-/post-changes in disease level and functional status, where negative change indicated improvement. Results: Results from 451 patients in this study indicated that 73% were female and, on average, were diagnosed with MS >11 years previously. Almost all (96%) patients had used one or more MS drugs prior to natalizumab initiation. After receiving natalizumab, 97% of all patients reported an improvement or remained stable in their overall QOL. Despite the short treatment duration, there were significant improvements (mean ± SD change) in disease level (−0.26 ± 0.99, paired t-test=5.47; p > 0.001) and functional status (−0.33 ± 0.73, paired t-test= 9.40; p > 0.001) scores. More than 80% of patients reported an improvement in one or more MSIS-29 physical items. The physical item on the adapted MSIS-29 with the highest reported improvement (58%) was ‘the ability to do physically demanding tasks’. The physical item with the lowest reported improvement (32%) was ‘problems using transport’. Conclusion: Overall, the experiences of MS patients with natalizumab were positive in a clinical practice setting. Patients reported improvements in overall QOL, ambulation and functional status as early as after three natalizumab infusions. While preliminary, these early results are suggestive of a beneficial effect of natalizumab in patients with MS and warrant further long-term investigation of the impact of this treatment on patient outcomes. Copyright Adis Data Information BV 2009

Suggested Citation

  • Siddhesh Kamat & Krithika Rajagopalan & Judith Stephenson & Sonalee Agarwal, 2009. "Impact of Natalizumab on Patient-Reported Outcomes in a Clinical Practice Setting," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 2(2), pages 105-112, June.
    • Handle: RePEc:spr:patien:v:2:y:2009:i:2:p:105-112
    DOI: 10.2165/01312067-200902020-00006
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/01312067-200902020-00006
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/01312067-200902020-00006?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:patien:v:2:y:2009:i:2:p:105-112. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.